bibliographicCitation |
Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation. 2007 Jun 15;83(11):1518–20. doi: 10.1097/01.tp.0000263393.65764.f4. PMID: 17565328. |